Drug Profile
Research programme: immunomodulators - Alivio Therapeutics
Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Alivio Therapeutics
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Arthritis in USA
- 23 May 2018 Alivio has patent protection for compositions of matter for its Inflammation-Targeting Technology Platform in the US
- 03 Apr 2018 Preclinical trials in Arthritis in USA (unspecified route) before April 2018